Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 871

Sort by

Sort Order Select

Journal Articles

How I incorporate novel agents into the treatment of classical Hodgkin lymphoma

Narendranath Epperla, Alex F. Herrera

Blood (2021) 138 (7): 520–530.

https://doi.org/10.1182/blood.2020007900

Published: 2021

Journal Articles

Mutational landscape of gray zone lymphoma

Blood (2021) 137 (13): 1765–1776.

https://doi.org/10.1182/blood.2020007507

Published: 2021

Includes: Supplemental data

Journal Articles

Spatial signatures identify immune escape via PD-1 as a defining feature of T-cell/histiocyte-rich large B-cell lymphoma

Blood (2021) 137 (10): 1353–1364.

https://doi.org/10.1182/blood.2020006464

Published: 2021

Includes: Supplemental data

Journal Articles

Pembrolizumab followed by AVD in untreated early unfavorable and advanced-stage classical Hodgkin lymphoma

Pamela B. Allen, Hatice Savas, Andrew M. Evens, Ranjana H. Advani, Brett Palmer, Barbara Pro, Reem Karmali, Eric Mou, Jeffrey Bearden, Gary Dillehay, Robert A. Bayer, Robert M. Eisner, Joan S. Chmiel, Kaitlyn O’Shea, Leo I. Gordon, Jane N. Winter

Blood (2021) 137 (10): 1318–1326.

https://doi.org/10.1182/blood.2020007400

Published: 2021

Includes: Supplemental data

Journal Articles

Immune escape mechanisms for TCRLBCL

Wing C. Chan

Blood (2021) 137 (10): 1274–1276.

https://doi.org/10.1182/blood.2020008766

Published: 2021

Journal Articles

Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab and venetoclax

Blood (2020) 135 (26): 2402–2412.

https://doi.org/10.1182/blood.2019004492

Published: 2020

Includes: Supplemental data

Journal Articles

Brentuximab vedotin with chemotherapy for stage III/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study

Blood (2020) 135 (10): 735–742.

https://doi.org/10.1182/blood.2019003127

Published: 2020

Includes: Supplemental data

Journal Articles

Genomic analyses of PMBL reveal new drivers and mechanisms of sensitivity to PD-1 blockade

Bjoern Chapuy, Chip Stewart, Andrew J. Dunford, Jaegil Kim, Kirsty Wienand, Atanas Kamburov, Gabriel K. Griffin, Pei-Hsuan Chen, Ana Lako, Robert A. Redd, Claire M. Cote, Matthew D. Ducar, Aaron R. Thorner, Scott J. Rodig, Gad Getz, Margaret A. Shipp

Blood (2019) 134 (26): 2369–2382.

https://doi.org/10.1182/blood.2019002067

Published: 2019

Includes: Supplemental data

Journal Articles

The microenvironmental niche in classic Hodgkin lymphoma is enriched for CTLA-4–positive T cells that are PD-1–negative

Sanjay S. Patel, Jason L. Weirather, Mikel Lipschitz, Ana Lako, Pei-Hsuan Chen, Gabriel K. Griffin, Philippe Armand, Margaret A. Shipp, Scott J. Rodig

Blood (2019) 134 (23): 2059–2069.

https://doi.org/10.1182/blood.2019002206

Published: 2019

Includes: Supplemental data

Journal Articles

Prevention and Management of Tumor Lysis Syndrome in Patients with CLL and Coexisting Conditions Treated with Venetoclax-Obinutuzumab or Chlorambucil-Obinutuzumab: Results from the Randomized CLL14 Trial

Othman Al-Sawaf, MD, Anna-Maria Fink, MD, Sandra Robrecht, PhD, Arijit Sinha, PhD, Maneesh Tandon, MD, Barbara F. Eichhorst, MD, Kirsten Fischer, MD, Michael Hallek, MD

Blood (2019) 134 (Supplement_1): 4315.

https://doi.org/10.1182/blood-2019-126570

Published: 2019

Journal Articles

Population-Based, Cause-Specific Risk of Non-Lymphoma Deaths Among 20,491 Adults with Classical Hodgkin Lymphoma (cHL) Treated with Initial Chemotherapy in the United States, 2000-2015

Graca M. Dores, MD, Rochelle E. Curtis, MA, Nicole H. Dalal, BA, Martha S. Linet, MD MPH, Lindsay M. Morton, PhD

Blood (2019) 134 (Supplement_1): 4034.

https://doi.org/10.1182/blood-2019-124831

Published: 2019

Journal Articles

Baseline Metabolic Tumor Volume in 18FDG-PET-CT Scans in Classical Hodgkin Lymphoma Using Semi-Automatic Segmentation

Julia Driessen, BSc, Gerben J.C. Zwezerijnen, MD, Jakoba J Eertink, MSc, Marie José Kersten, MD PhD, Anton Hagenbeek, MD PhD, Otto S Hoekstra, MD PhD, Josée M Zijlstra, MD PhD, Ronald Boellaard, MSc, PhD

Blood (2019) 134 (Supplement_1): 4049.

https://doi.org/10.1182/blood-2019-125495

Published: 2019

Journal Articles

IgM-Gammopathies Transformed into Aggressive Lymphoma: Incidence, Basal Clinical Features and Outcome of a Registry Based, Spanish Retrospective Series

Irene Dogliotti, MD, Cristina Jiménez, PhD, Federica Cavallo, MD PhD, Noemi Puig, MD PhD, Gian Maria Zaccaria, PhD, Veronica Gonzalez De La Calle, MD PhD, Maria Eugenia Sarasquete, PhD, Miguel Alcoceba, Pilar Delgado, MD, Maria Rosa López, MD, Aránzazu García Mateo, PhD, Simone Ferrero, MD, Mario Boccadoro, Marcos González, Ramón García-Sanz, MD PhD

Blood (2019) 134 (Supplement_1): 4011.

https://doi.org/10.1182/blood-2019-123353

Published: 2019

Journal Articles

The Use of CEP (Lomustine, Etoposide and Prednisone), an All-Oral Palliative Chemotherapy Regimen, in Aggressive Lymphomas

Lakshman Vasanthamohan, MD FRCPC, Brent Parker, MD, Joy Mangel, MD FRCPC, Selay Lam, MDBSc,FRCPC, Kang Howson-Jan, MD FRCPC, Chai Wye Phua, MD FRCPC

Blood (2019) 134 (Supplement_1): 4131.

https://doi.org/10.1182/blood-2019-126997

Published: 2019

Journal Articles

Utilization of Immune Checkpoint Inhibitors for Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL) in Oncology Community Practices

Ajeet Gajra, MD FACP, Andrew J Klink, PhD MPH, Chadi Nabhan, MDMBA, FACP, Bruce Feinberg, DO

Blood (2019) 134 (Supplement_1): 4057.

https://doi.org/10.1182/blood-2019-129632

Published: 2019

Journal Articles

Impact of Post-Transplant Consolidative Radiotherapy in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma and a PET-CT Based Predictive Model for Relapse

Collin Chin, MBBS, Andrew Wirth, MBBS, MD FRACP, FRANZCR, David Ritchie, MD PhD, Michael Hofman, MBBS (Hons), FRACP, FAANMS, Michael MacManus, John F. Seymour, MBBS, PhD FRACP, Belinda Campbell, MBBS, MMed, FRANZCR, Michael Dickinson, MBBS,FRACP,FRCPA

Blood (2019) 134 (Supplement_1): 4044.

https://doi.org/10.1182/blood-2019-122716

Published: 2019

Journal Articles

An Analysis from the WM UK Rory Morrison Registry: Waldenström's Macroglobulinaemia Patient Demographics, Disease Characteristics and Evolving Treatment Choices

Oliver Tomkins, BMBS, MRCP, Joshua Bomsztyk, Helen McCarthy, MBBS, PhD, Jaimal Kothari, Dima El-Sharkawi, Charalampia Kyriakou, Guy Pratt, Ali Rismani, MBBS, Shirley D'Sa

Blood (2019) 134 (Supplement_1): 4016.

https://doi.org/10.1182/blood-2019-129212

Published: 2019

Journal Articles

Safety and Toxicity Profile of Pembrolizumab (PEM) in Combination with ICE Chemotherapy Followed By Autologous Stem Cell Transplantation for Relapsed/Refractory Classical Hodgkin Lymphoma: No Impairment in Stem Cell Mobilization or Engraftment

Locke J. Bryan, MD, Scott E. Smith, MD PhD, Pamela Allen, MDMSc, Carla Casulo, Brett Alan Palmer, BS, Reem Karmali, MD, Barbara Pro, MD, Denise M Scholtens, PhD, Hatice Savas, MD, Jayesh Mehta, MD, Leo I. Gordon, MD, Jane N. Winter, MD

Blood (2019) 134 (Supplement_1): 4029.

https://doi.org/10.1182/blood-2019-123879

Published: 2019

Journal Articles

A Phase 2 Study of Retreatment with Brentuximab Vedotin in Patients with cHL, sALCL or Other CD30-Expressing PTCL

Sairah Ahmed, MD, Julie Lisano, PharmD, Trevor Newhook, MS

Blood (2019) 134 (Supplement_1): 4054.

https://doi.org/10.1182/blood-2019-121523

Published: 2019

Journal Articles

Brentuximab Vedotin with Chemotherapy for Stage 3/4 Classical Hodgkin Lymphoma (cHL): 4-Year Update of the Echelon-1 Study

Blood (2019) 134 (Supplement_1): 4026.

https://doi.org/10.1182/blood-2019-124116

Published: 2019

NARROW

How I incorporate novel agents into the treatment of classical Hodgkin lymphoma

Mutational landscape of gray zone lymphoma

Spatial signatures identify immune escape via PD-1 as a defining feature of T-cell/histiocyte-rich large B-cell lymphoma

Pembrolizumab followed by AVD in untreated early unfavorable and advanced-stage classical Hodgkin lymphoma

Immune escape mechanisms for TCRLBCL

Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab and venetoclax

Brentuximab vedotin with chemotherapy for stage III/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study

Genomic analyses of PMBL reveal new drivers and mechanisms of sensitivity to PD-1 blockade

The microenvironmental niche in classic Hodgkin lymphoma is enriched for CTLA-4–positive T cells that are PD-1–negative

Prevention and Management of Tumor Lysis Syndrome in Patients with CLL and Coexisting Conditions Treated with Venetoclax-Obinutuzumab or Chlorambucil-Obinutuzumab: Results from the Randomized CLL14 Trial

Population-Based, Cause-Specific Risk of Non-Lymphoma Deaths Among 20,491 Adults with Classical Hodgkin Lymphoma (cHL) Treated with Initial Chemotherapy in the United States, 2000-2015

Baseline Metabolic Tumor Volume in 18FDG-PET-CT Scans in Classical Hodgkin Lymphoma Using Semi-Automatic Segmentation

IgM-Gammopathies Transformed into Aggressive Lymphoma: Incidence, Basal Clinical Features and Outcome of a Registry Based, Spanish Retrospective Series

The Use of CEP (Lomustine, Etoposide and Prednisone), an All-Oral Palliative Chemotherapy Regimen, in Aggressive Lymphomas

Utilization of Immune Checkpoint Inhibitors for Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL) in Oncology Community Practices

Impact of Post-Transplant Consolidative Radiotherapy in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma and a PET-CT Based Predictive Model for Relapse

An Analysis from the WM UK Rory Morrison Registry: Waldenström's Macroglobulinaemia Patient Demographics, Disease Characteristics and Evolving Treatment Choices

Safety and Toxicity Profile of Pembrolizumab (PEM) in Combination with ICE Chemotherapy Followed By Autologous Stem Cell Transplantation for Relapsed/Refractory Classical Hodgkin Lymphoma: No Impairment in Stem Cell Mobilization or Engraftment

A Phase 2 Study of Retreatment with Brentuximab Vedotin in Patients with cHL, sALCL or Other CD30-Expressing PTCL

Brentuximab Vedotin with Chemotherapy for Stage 3/4 Classical Hodgkin Lymphoma (cHL): 4-Year Update of the Echelon-1 Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only